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 Oral direct anticoagulants such as DTIs,
but not vitamin K antagonist, diminish the
progression of atrial dilation associated
with heart failure in a rat model.
 Prevention of atrial dilation by DTI is
associated with decreased duration of
atrial arrhythmia induced by burst pacing.
 DTI inhibits interstitial ﬁbrosis,
extracellular matrix remodeling, and
hypertrophy of atrial myocardium.
 Plasma DTI concentrations inhibiting
atrial remodeling are lower than those
required for therapeutic anticoagulant
activity.
 DTIs may be of interest to prevent the
progression of atrial ﬁbrillation substrate
in addition to their anticoagulant activity.SERM), Unité Mixte de Recherche
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ABBAND ACRONYMS
AF = atrial ﬁbrillation
ANP = atrial natriuretic peptide
BNP = brain natriuretic peptide
CTGF = connective tissue
growth factor
DTI = direct thrombin inhibitor
MHC = myosin heavy chain
MI = myocardial infarction
c3 = nuclear factor of
(N
(FP
an
pa
MaThe present study tested the hypothesis that thrombin participates in formation of left atrial remodeling and
that direct oral anticoagulants, such as direct thrombin inhibitors (DTIs), can prevent its progression. In a rat
model of heart failure associated with left atrial dilation, we found that chronic treatment with DTIs reduces the
atrial remodeling and the duration of atrial ﬁbrillation (AF) episodes induced by burst pacing by inhibiting
myocardial hypertrophy and ﬁbrosis. In addition to the prevention of thromboembolism complicating AF, DTIs
may be of interest to slow down the progression of the arrhythmogenic substrate. (J Am Coll Cardiol Basic
Trans Science 2016;1:328–39) © 2016 The Authors. Published by Elsevier on behalf of the American College of
Cardiology Foundation. This is an open access article under the CC BY license (http://creativecommons.org/
licenses/by/4.0/).ted T cells 3NFAT
activaPAI = plasminogen activator
inhibitor
PAR = protease-activated
receptorA trial ﬁbrillation (AF) is the most common sus-tained cardiac arrhythmia encountered inclinical practice (1). It is associated with a
5-fold risk of stroke and systemic thromboembolisms.
During AF, thrombus formation is promoted by blood
stasis in poorly contractile atria together with a hyper-
coagulable state, as indicated by high circulating
levels of ﬁbrinolytic degradation products, plasmin-
ogen activator inhibitor (PAI)-1, and thrombin-
antithrombin complex (2). For all of these reasons,
anticoagulation is a central therapeutic target for
most AF patients. Anticoagulation can be achieved
via vitamin K antagonists or, more recently, with
direct thrombin inhibitors (DTIs) or direct factor Xa in-
hibitors, referred to as non–vitamin K antagonist oral
anticoagulants (3).SEE PAGE 340Thrombin is the central protease of the coagulation
cascade. It converts soluble plasma ﬁbrinogen into
insoluble clot-forming ﬁbrin polymers, and activates
several positive feedback steps to amplify its own
generation (4). In addition, thrombin has pleiotropic
cellular effects through the cleavage of protease-
activated receptor (PAR)-1, including hemostasis,
inﬂammation, cellular growth, and proliferation
(4–6). For instance, PAR-1 promotes hypertrophy of
neonatal rat cardiomyocytes and deoxyribonucleic
acid synthesis in ﬁbroblasts (5,7). In mice, PAR-1
overexpression induces eccentric hypertrophy and
dilated cardiomyopathy, whereas PAR-1 deﬁciency is
associated with reduced left ventricle dilation after
myocardial infarction (MI) (8).ational program “Investissements d’avenir”: ANR-10-IAHU-05); and the E
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are recognized to be involved in atrial
remodeling, including the renin angiotensin
system (9), but little is known about the role of
thrombin. In vitro, this protein induces alterations of
the electric and mechanical properties of rabbit left
atrial strips, which are prevented by the DTI dabiga-
tran and a PAR-1 antagonist (10). The present in vivo
study was undertaken to test the hypothesis that
thrombin participates in left atrial remodeling and AF
substrate formation, known to be promoted by heart
failure (11–13), and that DTI can slow their progression.
It was conducted using a rat model of heart failure
secondary to an extensive MI, which is associated with
left atrial remodeling and AF susceptibility (14,15). We
found that DTIs and PAR-1 antagonists prevent atrial
remodeling and reduce AF susceptibility.
METHODS
MODEL OF ATRIAL REMODELING FOLLOWING
INFARCTION-INDUCED HEART FAILURE. This study
had the approval of the local animal research ethics
committee and the French Ministry of Education and
Research (authorization N00429.03). Male OFA
Sprague-Dawley rats weighting 200 to 220 g were
obtained from Charles River Laboratories (L’arbresle,
France) and housed for 10 days before the surgery.
Animals were anesthetized with intraperitoneal
injection of 30 mg/kg sodium pentobarbital and
received a subcutaneous injection of 1.5 mg/kg
meloxicam for pain. MI was achieved by thoracotomy
and transient occlusion of the left anterioruropean Network for Translational Research in AF
CIFRE grant from the French Ministry of Education
ave no relationships relevant to the contents of this
work.
016, accepted May 2, 2016.
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330descending coronary artery. After 30 min of ischemia,
a deﬁnitive reperfusion phase was initiated. Sham
rats underwent thoracotomy only. This model of
heart failure was associated with a hypercoagulable
state, as indicated by plasma thrombogenic potential
assayed using calibrated automated thrombography
(Appendix). The endogenous thrombin potential was
similar at 5 and 56 days post-surgery for sham rats
and was increased in rats with MI at the 3 times
studied (Supplemental Figure 1).
TREATMENTS. Twice daily gavage with 12.5 mg/kg
dabigatran etexilate or its vehicle (40% polyethylene
glycol/60%H2O) and once-daily gavage with the PAR-1
antagonist F16618 (5 to 40 mg/kg) or its vehicle (1%
methylcellulose) started 1 h post-MI, when rats
regained consciousness. Warfarin was given orally in
drinking water at 5 to 6.25 mg/l and 7.5 to 10 mg/l
over 1 month, resulting in average doses of 0.43 and
0.64 mg/kg/day. Due to the high solubility of DTI
S35972 in saline (vehicle), doses of 1.5 to 15 mg/kg/day
were administered using ALZET osmotic minipumps
(DURECT Corporation, Cupertino, California), which
were subcutaneously implanted under anesthesia
following the surgery. Rats were weighed before sur-
gery, every week to adapt dabigatran or warfarin
dosage, at 4 weeks post-MI to adapt S35972 dosage
when changing the minipumps during anesthesia for
echography, and at the end of treatment.
Detailed descriptions of all other experimental
procedures are provided in the Appendix.
RESULTS
DTIs INHIBIT ATRIAL DILATION AND THE DEVELOPMENT
OF ARRHYTHMOGENIC SUBSTRATE. To study the effect
of DTIs on atrial remodeling, we ﬁrst examined the
effects of the oral DTI dabigatran etexilate, which
has potent antithrombotic activity in rats in the range
of 5 to 30 mg/kg (16). After 4 weeks of oral gavage,
the surface of the left atria measured by bidimen-
sional mode echocardiography increased 1.8-fold in
vehicle-treated rats with MI compared with sham
animals and only 1.3-fold in dabigatran-treated rats
with MI (Figure 1A). Remarkably, treatment with the
vitamin K antagonist, warfarin, did not signiﬁcantly
reduce left atrial dilation. Furthermore, dabigatran
etexilate slightly reduced the left ventricular dilation
without improving the systolic function evaluated by
fractional shortening and ejection fraction (Figure 1B).
The inhibitory effect of dabigatran on left atria size
was conﬁrmed by macroscopic examination at sacri-
ﬁce of the animals (Figure 1C).
Similar effects on atrial dilation were observed with
another DTI, the nonprodrug S35972, which hasanticoagulant and antithrombotic activities compara-
ble to dabigatran etexilate between 1 to 20mg/kg in rats
(16,17). In addition, because this drug is highly soluble,
it could be subcutaneously delivered via osmotic
minipumps, which is a less stressful and more reliable
route of delivery than oral gavage. Thus, S35972 was
used in the rest of the study. At 4 weeks post-MI, DTI
S35972 dose-dependently reduced the left atrial area,
which increased only 1.2-fold compared with sham
animals at the optimal dose of 6 mg/kg/day, without
any effect on left ventricle (Supplemental Figure 2A).
As PAR-1 is themain thrombin receptor in the heart (5),
we also tested the effect of the PAR-1 antagonist F16618
on atrial dilation. After 8 weeks of treatment, S35972
and F16618 dose-dependently diminished both left
atrial size and left ventricular diameter without an ef-
fect on the ventricular function (Figures 2A and 2B,
Supplemental Figures 2A and 2B). F16618 reduced the
ventricular diameter at the optimal dose of 10 mg/kg/
day (p ¼ 0.004 vs. vehicle-treated rats with MI),
whereas 6 mg/kg/day of S35972 had a little effect
(p ¼ 0.058). Furthermore, the duration of AF episode
triggered by burst pacing was prolonged in vehicle-
treated rats with MI but not in DTI-treated rats
(Figure 2C).
Remarkably, the DTI S35972 also reduced the atrial
dilation when the treatment started 1 month after the
constitution of the cardiomyopathy. A total of 4
weeks of treatment inhibited the progression of the
left atrial dilation. The atrial area increased 1.6-fold in
DTI-treated animals compared with shams instead of
2.1-fold in vehicle-treated rats with MI (Figure 2D),
with a trend of reduced average duration of AF from
6.75 s to 3.3 s (Figure 2E).
These results indicate that the DTIs inhibit and
prevent the progression of the atrial remodeling
associated with heart failure in rats.
DTIs REDUCE ATRIAL DILATION INDEPENDENTLY
OF THEIR ANTICOAGULANT PROPERTIES. We next
investigated the relationship between antiremodeling
and anticoagulant properties of DTIs. First, we
determined their availability in rat plasma by means
of mass spectrometry. In rats with MI treated with
25 mg/kg/day dabigatran etexilate or 6 mg/kg/day
S35972, the plasma concentrations ranged from 28 to
72 ng/ml at peak for dabigatran and 22 to 85 ng/ml for
S35972, which corresponds to the low therapeutic
levels of DTI detected in humans (18). The inhibition
of atrial dilation was maximal at DTI concentrations
ranging from 30 to 100 nmol/l as previously reported
for the inhibition of thrombin-mediated PAR-1
cleavage by dabigatran (19), but it decreased with
high plasma concentrations (Figure 3A). At the
FIGURE 1 Dabigatran Etexilate Reduces Left Atrial Area in MI-Induced Heart Failure
Sham rats and rats with myocardial infarction (MI) were treated over 4 weeks with 25 mg/kg/day dabigatran, 4.3 to 6.4 mg/kg/day warfarin, or vehicle (V). (A)
Representative echocardiographic images in bidimensional mode and individual values of left atrial area. (B) Images in time-motion mode of left ventricular end-diastolic
(LVED) diameters. (C) Representative pictures of left atria from sham rats and rats with MI at treatment end. n ¼ 5 to 10 for each condition. Exact p values in blue are
calculated versus sham, those in red versus vehicle-treated rats with MI, and the 1 in gray versus dabigatran-treated rats with MI.
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FIGURE 2 DTI S35972 Prevents Atrial Dilation and Reduces Arrhythmia Duration
S35972 or vehicle were administered for 8 weeks. (A) Dose-dependent effect on left atrial area measured by bidimensional-mode echocardiography. (B) Measurements
of left atrial and LVED diameters in time-motion mode. (C) Representative electrocardiographs and dose-dependent effect on pacing-induced atrial arrhythmia.
The arrow indicates the return to sinus rhythm. (D) Measurements of left atrial area and diameter and (E) arrhythmia duration after 4 weeks of treatment, which started
4 weeks post-MI. (A to C) n ¼ 5 to 15 for each condition. (D to E) n ¼ 3 to 5, 8, and 4 to 6 for sham rats, vehicle-treated rats with MI, and S35972-treated rats with MI,
respectively. *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001; exact p values calculated versus sham are in blue, and those versus vehicle-treated rats
with MI are in red. Exact p values in black compared data before and after treatment. Abbreviations as in Figure 1.
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FIGURE 3 The Antiremodeling Properties of DTIs Are Independent of Their Anticoagulant Activity
Treatment was with either 25 mg/kg/day dabigatran etexilate for 4 weeks or S35972 for 8 weeks at doses ranging 1.5 to 15 mg/kg/day. Direct
thrombin inhibitor (DTI) plasma concentrations were assessed by liquid chromatography-tandem mass spectrometry. Inhibition of atrial dilation
(A) and thrombin time increase (B) were calculated as described in the Appendix.
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333opposite end, the anticoagulant activity assessed by
thrombin times increased with DTI plasma concen-
trations (Figure 3B). These results suggest that the
antiremodeling effects of DTI are independent of
their anticoagulant activity.
DTI INHIBITS REMODELING OF ATRIAL EXTRACELLULAR
MATRIX. We next examined the histological de-
terminants of the effect of DTI on atrial remodeling.
Masson trichrome staining of atrial cross sections from
vehicle-treated rats with MI revealed an overall hy-
pertrophy of themyocardium, with enlargedmyocytes
and interstitial ﬁbrosis as indicated by arrows in
Figure 4A. In atria from rats with MI treated with DTI
for 8 weeks, myocyte hypertrophy was markedly
reduced and ﬁbrosis was barely detectable. Staining of
subendocardial and interstitial collagens with pic-
rosirius red conﬁrmed an increase in interstitial
ﬁbrosis in vehicle-treated rats withMI and a signiﬁcant
decrease in DTI-treated rats with MI (Figure 4B). We
then analyzed the effect of DTIs on messengerribonucleic acid (mRNA) expression using rat gene-s-
peciﬁc primers (Supplemental Table 1). First, we
studied mRNA expression of connective tissue growth
factor (CTGF), which is involved in the remodeling of
extracellular matrix (20) and is up-regulated in AF
patients (21). Post-MI treatments for 1 and 2 months
prevented the up-regulation of CTGF in left atria, and
treatment initiated 1 month after the MI tended to
decrease mRNAs (Figure 4C). We also analyzed the
expression of PAI-1, which has both thrombogenic and
ﬁbrogenic activities (2,20). Post-MI treatment for 2
months abolished the induction of PAI-1 in the left
atria (Figure 4D), but it had no effect on both PAI-1 and
CTGF mRNAs in the left ventricle (Figure 4E). These
observations suggest that DTIs are able to prevent the
extracellular matrix remodeling in the left atria but not
in the left ventricle.
DTI PREVENTS ATRIAL MYOCARDIAL HYPERTROPHY,
AS DOES PAR-1 ANTAGONIST. We further characterized
the antihypertrophic effect of DTI by measuring
FIGURE 4 DTIs Reduce Myocardial and Matrix Remodeling in Left Atria
Rats with MI were treated with vehicle or 25 mg/kg/day dabigatran etexilate for 4 weeks or 6 mg/kg/day S35972 for either 8 or 4 weeks, with
initiation of treatment 1 month after MI (shifted 4 weeks). (A) Masson trichrome or (B) picrosirius red staining of atrial sections. Representative
images were from the same rat in each group (n ¼ 5 to 7). Magniﬁcation was 100 and 600. Atrial (C and D) and ventricular (E) messenger
ribonucleic acid (mRNA) of connective tissue growth factor (CTGF) and plasminogen activator inhibitor 1 (PAI-1) were measured by real-time
polymerase chain reaction. n ¼ 3 to 11; exact p values in blue are calculated versus sham rats and those in red versus vehicle-treated rats with
MI. Abbreviations as in Figures 1 and 2.
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334myocyte diameters in left atrial cross sections labeled
with wheat germ agglutinin to stain plasma mem-
brane. As illustrated in Figure 5A, atrial myocyte
diameter increased 1.4-fold in the atria fromvehicle-treated rats with MI compared with atria of
S35972-treated and sham rats. Myocardial hypertro-
phy is associated with the reappearance of fetal
phenotype including the expression of b-myosin
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335heavy chain (MHC) and natriuretic peptides (22). At 8
weeks post-MI, b-MHC transcripts signiﬁcantly
increased, whereas the a isoform (a-MHC) did not
change in dilated atria of vehicle-treated rats
(Figure 5B). In addition, the mRNA level of brain
natriuretic peptide (BNP) was increased, but not that
of atrial natriuretic peptide (ANP). In sharp contrast,
there was no change in b-MHC and BNP in atria from
rats with MI treated with either the DTI S35972 or the
PAR-1 antagonist F16618 in comparison with sham
animals (Figures 5B and 5C). Of note, S35972 also
down-regulated the expression of these markers in the
ventricles of rats with MI (Supplemental Figure 3). We
next analyzed whether PAR-1 expression was
increased in rats with MI. Levels of both mRNA and
protein were similar in the 3 groups of rats (Figures 5D
and 5E), conﬁrming activation of PAR-1 signaling in
dilated atria. Among the transcription factors acti-
vated by PAR-1 (23), the nuclear factor of activated
T cells 3 (NFATc3) is involved in maladaptive hyper-
trophy associated with heart failure (24) and
thrombin-induced gene expression (25). DTI treatment
prevented an MI-induced increase in the active
form of NFATc3 (Figure 5E). These results suggest
that the hypertrophic remodeling of atrialmyocardium
is partly due to an over activation of PAR-1 by
thrombin.
THROMBIN AND PAR-1 TRIGGER HYPERTROPHIC
SIGNALS VIA THE RHO/RHO KINASE PATHWAY. To
conﬁrm the direct role of thrombin in atrial hypertro-
phy, we investigated its action in left atrial explants
from control rats. This ex vivo model eliminated the
possibility that mediators other than thrombin partic-
ipate in the in vivo effects of DTI or PAR-1 antagonist.
After 7 days of stimulation with 10 nmol/l thrombin,
b-MHC but not a-MHC mRNAs were up-regulated, and
this induction was prevented by F16618 (Figure 6A).
Moreover, thrombin enhanced the expression of BNP
and ANP transcripts and the release of soluble BNP
through PAR-1 (Figures 6B and 6C). It also increased
PAI-1 mRNAs (Figure 6D). Among the various
PAR-1 effectors (23), the Rho-associated protein kinase
(ROCK) is known to be involved in thrombin-induced
endothelial permeability (26) and cardiomyocyte
growth (27). Addition of the ROCK inhibitor Y27632
together with thrombin down-regulated BNP, ANP,
and PAI-1 and reduced BNP secretion (Figures 6B
to 6D). ROCK is a downstream effector of RhoA,
which also activates the signal transducer and acti-
vator of transcription 3 (Stat3) (23). As expected, Stat3
is phosphorylated upon thrombin exposure, and both
PAR-1 antagonist and ROCK inhibitor prevented this
activation (Figure 6E). Altogether, these resultsindicate that thrombin/PAR-1 induce atrial hypertro-
phic phenotypes through the Rho cascade.
DISCUSSION
The major ﬁnding of the present study is that chronic
thrombin inhibition with DTIs prevents the atrial
remodeling and the AF susceptibility associated with
heart failure in a rat model independently of their
anticoagulant properties. This thrombin effect on
atrial myocardium is mediated by PAR-1 signaling
pathways, which are involved in the hypertrophy and
ﬁbrosis of atrial myocardium.
The inhibition of the atrial remodeling observed
with DTI and PAR-1 antagonist cannot be attributed to
the improvement of left ventricle function. Indeed,
only a reduction of left ventricular end-diastolic
diameter without recovery of systolic function was
observed in treated animals. First, the large ﬁbrotic
scar of the infarcted left ventricle could have pre-
cluded any signiﬁcant improvement of left ventricu-
lar function. Second, it has been shown that once
established, atrial remodeling is no more sensitive to
hemodynamic conditions in this model (9). However,
PAR-1 deletion is associated with reduced left
ventricle dilation and less impairment of ventricular
function after MI in a PAR-1-knockout mouse line.
This discrepancy could be due to the fact that PAR-1
deletion suppresses all the signaling pathways of
the receptor, whereas DTI and antagonist block PAR-1
activation only by serine-proteases. Indeed, PAR-1 is
activated by thrombin and other coagulation factors,
but also by the matrix metalloproteinases at nonca-
nonical sites (6).
THROMBIN INHIBITION PREVENTS THE DEVELOPMENT
OF ATRIAL HYPERTROPHY AND FIBROSIS. The effects of
DTI and PAR-1 antagonist on the atrial remodeling of
rats with MI appears to be due to the inhibition of both
myocardial hypertrophy and ﬁbrosis. At the molecular
level, both treatments normalize the BNP expression
and b-MHC/a-MHC ratio, which are hallmarks of the
reprogramming fetal gene program in diseased atria
(22). DTI also decreased the levels of active NFATc3. In
addition, the hypertrophic effect of thrombin on atrial
myocardiumwas demonstrated ex vivo independently
of the other neuro-mediators and hormones activated
during heart failure. In left atrial explants, thrombin
stimulated the expression of b-MHC, BNP, and PAI-1
through PAR-1 and the Rho/ROCK/Stat3 pathway. Our
results are consistent with in vitro studies that showed
stimulation by thrombin of hypertrophic car-
diomyocyte growth and BNP production through
PAR-1 and Rho cascade (7,27). They also agree with a
previous report of an increased nuclear accumulation
FIGURE 5 Thrombin and PAR-1 Contribute to Atrial Dilation By Stimulating Atrial Myocardium Hypertrophy
Treatment with 6 mg/kg/day S35972, 10 mg/kg/day F16618, or vehicle lasted 8 weeks. (A) Immunoﬂuorescence images and quantiﬁcation of left atrial cross sections
stained with 4’,6-diamidino-2-phenylindole (blue) and wheat germ agglutinin (green). (B to D) Real-time polymerase chain reaction analysis of relative mRNA
expression for b- and a-myosin heavy chain (MHC), brain natriuretic peptide (BNP) and atrial natriuretic peptide (ANP), and protease-activated receptor-1 (PAR-1). (E)
Immunoblots of PAR-1 and nuclear factor of activated T cells 3 (NFATc3) and densitometric analysis. n ¼ 5 to 14 for each group; exact p values in blue are calculated
versus sham rats and those in red versus vehicle-treated rats with MI. Abbreviations as in Figures 1 and 3.
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336of active NFATc3 and re-expression of hypertrophic
genes in atrial myocardium from patients with chronic
persistent AF (28). Furthermore, our observations
that DTIs decrease interstitial ﬁbrosis and atrial
expression of PAI-1 and CTGF are consistent with a
previous study showing a reduction of CTGF andpulmonary ﬁbrosis by dabigatran (29). It is known
that thrombin/PAR-1 stimulate the calcineur-
in/NFATc and RhoA pathways (23). Both are involved
in cardiac hypertrophy and heart failure (24,27), and
RhoA regulates the endothelial permeability (26).
During heart failure, thrombin activates the RhoA
FIGURE 6 Rho Kinase and Transcription Factor Stat3 Are Involved in Thrombin-Mediated Hypertrophic Signals
Left atrial explants were cultured for 7 days. Real-time polymerase chain reaction analysis of relative mRNA expression for b and a isoforms of
MHC (A), BNP and ANP (B) and PAI-1 (D). (C) Quantiﬁcation of soluble BNP by enzyme-linked immunosorbent assay. (E) Immunoblots of
phosphorylated (P-) and total stat3. n ¼ 3 to 7 for each condition; exact p values in blue are calculated versus untreated atria and those in red
versus thrombin-stimulated atria. Abbreviations as in Figures 4 and 5.
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337signaling to stimulate its extravasation through the
endocardium and to induce remodeling of atrial
myocardium (Visual Abstract).
DUAL ANTIREMODELING AND ANTICOAGULANT
PROPERTIES OF DTIs. In the present study, the
anticoagulant activity of DTIs was directly correlated
to their plasma concentrations, whereas their anti-
remodeling effect was maximal between 35 to
100 nmol/l and decreased at higher concentrations.
Furthermore, we showed that 10 nmol/l thrombin, a
concentration reached during the initiation phase of
coagulation cascade (30), was sufﬁcient to inducehypertrophic genes in atrial myocardium in vitro.
Interestingly, maximal inhibition of PAR-1 cleavage is
obtained in vitro with 30 to 100 nmol/l dabigatran
and 10 nmol/l thrombin, whereas higher DTI con-
centrations have activating effects (19). It is known
that PAR-1 is activated at subnanomolar thrombin
concentrations (31). Altogether, these data suggest
distinct dose-dependency between the anticoagulant
and antiremodeling effects of the DTIs. Indeed, they
could inhibit the cellular actions of thrombin via
PAR-1 before activation of coagulation cascade and
formation of intra-atrial thrombus. In dilated and
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: AF is
associated with a high risk of systemic thromboem-
bolism due to blood stasis in poorly contractile atria
and a hypercoagulable state. Hence, most AF patients
are under anticoagulant therapies. In an animal model,
DTIs, including dabigatran, prevent or even reverse
the atrial remodeling and AF susceptibility associated
with heart failure by reducing atrial remodeling. This
PAR-1–mediated effect is independent of anticoagu-
lation properties of DTI.
TRANSLATIONAL OUTLOOK: The ongoing COM-
MANDER HF trial investigates whether targeted
reduction of thrombin generation may improve clinical
outcomes of patients with heart failure and coronary
artery diseases. Its results should afﬁrm or invalidate
the clinical translation prospects of our observations
in a rat model of heart failure-associated atrial
remodeling.
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thrombus, it is likely that such a low level of
thrombin is reached. In this line, DTI plasma con-
centrations, which inhibit atrial dilation in rats (28 to
75 ng/ml at peak and 22 to 85 ng/ml at steady-state)
correspond to the low therapeutic levels in humans.
For example, DTI plasma levels, which have been
measured in the RE-LY (Randomized Evaluation of
Long-Term Anticoagulation Therapy) trial, ranged
from 2 to 1,000 ng/ml at peak and 1 to 809 ng/ml at
steady-state for the high dose of 150 mg dabigatran
etexilate twice daily (18).
STUDY LIMITATIONS. The relevance of our experi-
mental data to the human AF cannot be ﬁrmly
established. They were obtained in a model of atrial
remodeling, which develops with HF but not with
spontaneous atrial arrhythmias. In some samples of
human right atria from patients with paroxysmal AF,
dilated atria, and normal ejection fraction
(Supplemental Table 2), we analyzed mRNA expres-
sion of PAI-1 and hypertrophic genes using human
gene-speciﬁc primers (Supplemental Table 3). PAI-1
and b-MHC/a-MHC ratio were increased, whereas the
anticoagulant thrombomodulin was decreased
(Supplemental Figure 4). This suggests a potential
thrombin accumulation in dilated atria, because
thrombomodulin accelerates its degradation (32).
This is also consistent with a previous study on hu-
man atria that reported PAI-1 induction by the coag-
ulation factor Xa in combination with rapid pacing of
human atrial slice (33). Clinical studies on DTI have
mainly evaluated the frequencies of stroke and major
bleeding, and as speciﬁed for the large RE-LY trial,
the case report forms were not prospectively
designed to collect echocardiogram details (34). The
current RE-CIRCUIT (Randomized Evaluation of
dabigatran etexilate Compared to warfarIn in pul-
monaRy vein ablation: assessment of different
peri-proCedUral antIcoagulation sTrategies) (35) and
COMMANDER HF (A Study to Assess the Effectiveness
and Safety of Rivaroxaban in Reducing the Risk of
Death, Myocardial Infarction or Stroke in Participants
With Heart Failure and Coronary Artery Disease
Following an Episode of Decompensated Heart Fail-
ure) trials (36) should help answer the question of
whether DTIs can reverse cardiac remodeling in
humans. RE-CIRCUIT evaluates the use of uninter-
rupted dabigatran etexilate during ablation pro-
cedures in patients with permanent or paroxysmal AF
(35). COMMANDER HF assesses the efﬁcacy of a low
dose of direct factor Xa inhibitor in reducing all-cause
mortality in HF patients with coronary artery disease
(36). Finally, we provided no information on the exactmechanism by which DTIs reduce arrhythmia dura-
tion in our model. The antiﬁbrillatory effect of DTIs
might be explained by the effect of thrombin on car-
diac ion currents, such as the activation of late
component of sodium current in atrial myocytes
(37,38).
CONCLUSIONS
There is a strong drive to understand mechanisms
underlying the aggravation of arrhythmia and the
transition from paroxysmal to permanent AF. The
present study provides the ﬁrst evidence for a role
in vivo of thrombin/PAR-1 signaling in the devel-
opment of atrial dilation and arrhythmogenic sub-
strate. Our ﬁnding that thrombin contributes to the
aggravation of atrial hypertrophy and ﬁbrosis points
out a novel potential therapeutic application for
DTIs that is independent of their anticoagulant
activity.
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